MVC si eaioadtcss hwit nngfetcii rnoag anlrpstnta aet.nptsi CVM si mdntirtstae via eslaxu ctnc,oat garon srnntal,atp ro raytellicv aiv ecplan.at nivaocetiRta of VCM rscouc ni the ospiesupmner.umsd
gnaOr plantrsnta nsipeatt rea at an eiearnsdc skri fo CVM mno.nepuai
he asw reven evign lvcaorgiicn - i deus that sa a ecul voer plntnsarta cejorneti
Wyh dluwo tshi ont be uetca nnrttaalsp eijtecorn elgadin ot AD?RS The rateneinic is e,eaedvlt nad I ese any onaser hyw it duwol be edvteael eydbon enocrjite
via @sammyj98 via UpToDate:
Universal prophylaxis with valganciclovir
or ganciclovir
is typically given to patients at risk for cytomegalovirus (CMV) reactivation (eg, seropositive recipients and those with seropositive donors). The duration of therapy often depends on the type of organ transplanted, the risk status of the patient, and individual institutional practice. Some transplant centers prefer to use a pre-emptive approach (eg, routine CMV viral load monitoring within initiation of treatment when reactivation becomes evident) for specific patient populations.
submitted by โamorah(115)
It can be re-accessed by making a purchase.
Purchase your membership here
$279$49 65% OFFeFerv &;gt- lreu uto lfet crnlavertui iulrfea MTP-SX M ypoialxprhs -t;&g uelr tou ssmtiuoeycPn e ocyidnirevKji aastlrntpn but on RBC/BWC in eirnu ;t-&g rlue uto stlnnarpta ticjneore
nvegLia MCV nad acltiapy uiymoaecbmrct as the aiennrmgi owt ts.oinop CMV is moer ilylke in a alarntsnpt attpe.ni
$279$49 65% OFF